FrancophonIA/ELRC3.0 huggingface dataset:
English: Your doctor may lower the dose or the speed of the infusion based on your response during the treatment.
Estonian: Teie arst võib olenevalt teie ravivastusest vähendada annust või aeglustada infusiooni.
English: Thaw Brineura and flushing solution
Estonian: Sulatada Brineura ja loputuslahus
English: Brineura and the flushing solution must only be administered by the intracerebroventricular route.
Estonian: Brineura't ja loputuslahust võib manustada ainult intratserebroventrikulaarselt (ajuvatsakestesiseselt).
English: No prominent ataxia, no pathologic falls.
Estonian: 3 Üldiselt normaalne kõnnak.Puudub märgatav ataksia, ilma patoloogiliste kukkumisteta.
English: Brineura and flushing solution vials should be thawed prior to administration.
Estonian: Brineura ja loputuslahuse viaalid tuleb enne manustamist sulatada.
English: Brineura and the flushing solution are solutions for infusion.
Estonian: Brineura ja loputuslahus on infusioonilahused.
English: Initiate infusion of the flushing solution at a rate of 2.5 ml per hour.
Estonian: Alustada infusiooni loputuslahusega kiirusel 2,5 ml tunnis.
English: Verify that the “Brineura” syringe in the syringe pump is empty after the infusion is complete.
Estonian: Pärast infusiooni lõppu veenduda, et süstlapumbas olev Brineura süstal on tühi.
English: Each vial of Brineura contains 150 mg of cerliponase alfa* in 5 ml of solution.
Estonian: Üks Brineura viaal sisaldab 150 mg alfatserliponaasi* 5 ml lahuses.
English: Each vial of Brineura contains 150 mg of cerliponase alfa in 5 ml of solution.
Estonian: Üks Brineura viaal sisaldab 150 mg alfatserliponaasi 5 ml lahuses.
English: Healthcare professionals should inspect the scalp for skin integrity to ensure the intracerebroventricular access device is not compromised prior to each infusion.
Estonian: Enne iga infusiooni peavad tervishoiuspetsialistid kontrollima peanaha seisundit, et tagada ajuvatsakestesisese ligipääsu seadme korrasolek.
English: CSF Pleocytosis Dropped head syndrome
Estonian: Tserebrospinaalvedeliku pleotsütoos Pea allalangemise sündroom
English: Administer the flushing solution provided after the Brineura infusion is complete.
Estonian: Loputuslahus tuleb manustada pärast Brineura infusiooni lõpetamist.
English: These naturally occurring particles are cerliponase alfa.
Estonian: Need on alfatserliponaasile omased osakesed.
English: Table 2: Frequency of adverse reactions with Brineura
Estonian: Brineura kõrvaltoimete esinemissagedus
English: Preparation for administration of Brineura and flushing solution
Estonian: Brineura ja loputuslahuse ettevalmistamine manustamiseks
English: Total dose administered every other week (mg)
Estonian: Üle nädala manustatav koguannus (mg)
English: Brineura will be given by a doctor with knowledge of giving medicines by intracerebroventricular use (infusion into the fluid of the brain) in a hospital or clinic.
Estonian: Brineura't manustab haiglas või kliinikus ravimite ajuvatsakesesiseses manustamises (ajuvedelikku infundeerimises) kogenud arst.
English: Vial (type I glass) with a stopper (butyl rubber), a flip-off cap (polypropylene) and crimp seal (aluminium).
Estonian: I tüüpi klaasist viaal butüülkummist punnkorgi, eemaldatava polüpropüleenkatte ja gofreeritud alumiiniumümbrisega.
English: Brineura and flushing solution excipients: Sodium phosphate dibasic heptahydrate; Sodium dihydrogen phosphate monohydrate; Sodium chloride;
Estonian: Brineura ja loputuslahuse abiained: kahealuseline naatriumfosfaatheptahüdraat; naatriumdivesinikfosfaatmonohüdraat; naatriumkloriid; kaaliumkloriid; magneesiumkloriidheksahüdraat; kaltsiumkloriiddihüdraat; süstevesi.
English: Breastfeeding should be discontinued during treatment with Brineura.
Estonian: Ravi ajal Brineura'ga tuleb imetamine katkestada.
English: Vomiting
Estonian: Krambihoodb
English: Intracerebroventricular use
Estonian: Intratserebroventrikulaarne
English: CSF protein increased ECG abnormalities CSF protein decreased
Estonian: Tserebrospinaalvedeliku valgusisalduse suurenemine EKG kõrvalekalded Tserebrospinaalvedeliku valgusisalduse vähenemine
English: Common side effects: pain rash hives head dropping (so that the chin drops towards the chest) stomach pain leakage of the device mouth or tongue blisters swelling or redness of the eyelid and the white part of the eye feeling nervous disorder of the stomach or intestines
Estonian: Sagedad kõrvaltoimed: - valu - lööve - nõgestõbi - pea allalangemine (lõua langemine rinnale) - kõhuvalu - seadme leke
English: Signs that you or your child may have an infection include fever, headache, neck stiffness, light sensitivity, nausea, vomiting, and change in mental status.
Estonian: peavalu, kaela kangus, valgustundlikkus, iiveldus, oksendamine ja vaimse seisundi muutus.
English: Flushing solution for Brineura Intracerebroventricular use
Estonian: Brineura loputuslahus Intratserebroventrikulaarne
English: How Brineura works
Estonian: Kuidas Brineura toimib
English: Language
Estonian: Keel
English: LOT:
Estonian: NN:
English: Device leakage Device occlusiond Device dislocatione Needle issuef
Estonian: Seadme probleem: seadme leke seadme sulgusd seadme paigalt nihkuminee Nõelaprobleemf
English: Administer flushing solution after Brineura.
Estonian: Manustada Brineura enne loputuslahust.
English: Talk to your doctor if you have any questions about your device.
Estonian: Kui teil on seadme kohta küsimusi, pidage nõu oma arstiga.
English: How Brineura is given
Estonian: Kuidas Brineura't manustatakse
English: Intracerebroventricular infusion of the flushing solution
Estonian: Loputuslahuse ajuvatsakestesisene infusioon
English: What you need to know before you or your child is given Brineura 3.
Estonian: 1. Mis ravim on Brineura ja milleks seda kasutatakse 2. Mida on vaja teada enne Brineura manustamist teile või teie lapsele 3.
English: Very common Common
Estonian: Väga sage Sage
English: Convulsion eventsb Headache
Estonian: Brineura annus ja maht
English: Talk to your doctor before you or your child is given Brineura.
Estonian: Enne kui teile või teie lapsele manustatakse Brineura't, pidage nõu oma arstiga.
English: The exposure to these substances is respectively estimated to 565,000 patient-years, 555,470 patient-years and 66,052 patient-years worldwide.
Estonian: Nende ravimite ekspositsioon kogu maailmas on hinnanguliselt vastavalt 565 000 patsiendiaastat, 555 470 patsiendiaastat ja 66 052 patsiendiaastat.
English: This is further supported by the likely common mechanism of action.
Estonian: Seda toetab samuti tõenäoliselt sama toimemehhanism.
English: In addition treatment should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses.
Estonian: Lisaks tuleb ravi katkestada patsientidel, kes hospitaliseeritakse oluliste kirurgiliste protseduuride või ägedate meditsiiniliste haiguste tõttu.
English: Further, in a number of cases, blood glucose values were only moderately increased or normal.
Estonian: Peale selle oli mitmel juhul veresuhkru väärtus ainult mõõdukalt suurenenud või normaalne.
English: Overall the reported cases were poorly documented and the MAHs are requested to implement targeted follow up questionnaires, in order to document consistent information on the cases.
Estonian: Üldiselt olid teatatud juhud halvasti dokumenteeritud ja müügiloa hoidjatel palutakse kasutada suunatud järelkontrolli küsimustikke, et dokumenteerida juhtude kohta järjepidev teave.
English: This can be partially buffered with the bicarbonate buffering system, but this system is quickly overwhelmed and other mechanisms must work to compensate for the acidosis.
Estonian: Seda saab osaliselt puhverdada bikarbonaatpuhvri süsteemiga, kuid see süsteem ammendatakse kiiresti ja atsidoosi kompenseerimiseks peavad töötama muud mehhanismid.
English: Although the MAHs estimated slightly different incidence rates, these were not all calculated according to the international standards for computation of incidence rate.
Estonian: Kuigi müügiloa hoidjad prognoosisid veidi erinevaid esinemissagedusi, ei olnud need kõik arvutatud esinemissageduse arvutamise rahvusvaheliste standardite kohaselt.
English: The RMP of all these products should be updated accordingly.
Estonian: Kõigi ravimite riskijuhtimiskavad tuleb vastavalt uuendada.
English: Taking into account the severity of these cases and the general pattern seen across these medicinal products, the European Commission requested, on the 10 of June 2015 and pursuant to Article 20 of Regulation No 726/2004, the opinion of the Agency on whether the marketing authorisation of canagliflozin-, dapagliflozin- and empagliflozin-containing medicinal products, should be maintained, varied, suspended or revoked.
Estonian: Arvestades nende juhtude raskust ja nende ravimite puhul täheldatud üldist mustrit, küsis Euroopa Komisjon määruse nr 726/2004 artikli 20 kohaselt 10. juunil 2015 kanagliflosiini, dapagliflosiini ja empagliflosiini sisaldavate ravimite müügilubade säilitamise, muutmise, peatamise või tühistamise kohta Euroopa Ravimiameti arvamust.
English: Having reviewed the PRAC recommendation, the CHMP agrees with the PRAC overall conclusions and grounds for recommendation.
Estonian: Olles tutvunud ravimiohutuse riskihindamiskomitee soovitusega, nõustus inimravimite komitee üldjäreldustega ja soovituse alustega.
English: Diabetic ketoacidosis (DKA) is a serious, often life-threatening condition, which usually develops in diabetic patients when insulin levels are too low.
Estonian: Diabeetiline ketoatsidoos (DKA) on raske, sageli eluohtlik seisund, mis tavaliselt tekib diabeetilistel patsientidel siis, kui organismi insuliinisisaldus on liiga väike.
English: In the EU, three SGLT2 inhibitors are currently authorised as monocomponent and as fixed dose combination with metformin: canagliflozin (Invokana and Vokanamet), dapagliflozin (Forxiga and Xigduo) and empagliflozin (Jardiance and Synjardy).
Estonian: ELis on käesoleval ajal saanud müügiloa kolm SGLT2 inhibiitorit monokomponentse ravimina ja fikseeritud annusega ravimina koos metformiiniga: kanagliflosiin (Invokana ja Vokanamet), dapagliflosiin (Forxiga ja Xigduo) ja empagliflosiin (Jardiance ja Synjardy).
English: No definite conclusion could be drawn regarding dose relationship or protective or exacerbating effect of concomitant medicines.
Estonian: Ei saa teha lõplikke järeldusi seose kohta annusega või kaasuvate ravimite protektiivse või raskendava toime kohta.
English: A search in Eudravigilance (EV) database was performed by the EMA on 19 May 2015 for the three SGLT2 inhibitors.
Estonian: Euroopa Ravimiamet tegi 19. mail 2015 Eudravigilance'i (EV) andmebaasis kolme SGLT2 inhibiitori kohta otsingu.
English: Based on the data available, the PRAC considered that there was no indication of a different risk between the products.
Estonian: Ravimite riskihindamiskomitee leidis olemasolevate andmete alusel, et puuduvad viited riskide erinevusele ravimite vahel.
English: By blocking the action of SGLT2, these substances cause more glucose to be removed via the urine, thereby reducing the levels of glucose in the blood via an insulinindependent mechanism.
Estonian: SGLT2 toimet blokeerides suurendavad need ained glükoosi eritumist uriiniga, mis vähendab glükoosisisaldust veres insuliinist sõltumatu mehhanismi kaudu.
English: SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen.
Estonian: SGLT2 ekspresseeritakse proksimaalsetes neerutuubulites ja selle osalusel reabsorbeerub enamik filtreeritud glükoosi tuubulite valendikust.
English: In absence of insulin the metabolism switches from using glycogenolysis to lipolysis as a source of energy, which produces ketone bodies.
Estonian: Insuliini puudumisel lülitub ainevahetus ümber glükogenolüüsi kasutamiselt lipolüüsile energiaallikana, mis tekitab ketokehasid.
English: Moreover, risk factors reported in the cases are consistent with those previously reported in the literature and the risks factors inherent to the patient population (e.g. patients with low beta-cell function reserve, restricted food intake or severe dehydration, sudden reduction in insulin dose and increased insulin requirements due to acute medical illness, surgery or alcohol abuse).
Estonian: Lisaks on diabeetilise ketoatsidoosi juhtude korral teatatud riskitegurid kooskõlas varem kirjanduses teatatud riskiteguritega ja patsiendipopulatsioonile omaste riskiteguritega (nt beetarakkude funktsiooni väikese reserviga patsiendid, piiratud toidutarbimine või raske dehüdratsioon, insuliiniannuse äkiline vähenemine ja insuliinivajaduse suurenemine ägeda haiguse või operatsiooni tõttu või alkoholi kuritarvitamine).
English: • The PRAC considered the procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data for SGLT2 inhibitors-containing medicinal products.
Estonian: • ravimiohutuse riskihindamiskomitee arutas määruse (EÜ) nr 726/2004 artikli 20 kohast menetlust, mis käsitles SGLT2 inhibiitoreid sisaldavate ravimite ravimiohutuse järelevalve andmeid.
English: Moreover, the MAHs should explore the feasibility of collecting plasma hormones in new or ongoing trials with the aim to identify patterns of hormone derangement that could further explain the mechanism of action of SGLT2 inhibitors in ketoacidosis.
Estonian: Veel peavad müügiloa hoidjad uurima plasmahormoonide määramise teostatavust uutes või käimasolevates uuringutes eesmärgiga tuvastada hormoonhäirete mustrid, mis võivad edasi selgitada SGLT2 inhibiitorite toimemehhanismi ketoatsidoosi korral.
English: In a number of these reports, the presentation of the condition was atypical with only moderately increased blood glucose levels observed.
Estonian: Mitmes teates oli seisund väljendunud ebatüüpiliselt koos ainult mõõdukalt suurenenud veresuhkrusisaldusega.
English: DKA most commonly occurs in patients with type 1 diabetes mellitus (T1DM) and is usually accompanied by high blood glucose levels (>250 mg/dL).
Estonian: Diabeetiline ketoatsidoos esineb kõige sagedamini 1. tüüpi diabeediga (T1DM) patsientidel ja sellega kaasneb tavaliselt suur veresuhkrusisaldus (> 250 mg/dl).
English: In view of the above, the PRAC considered that the benefit-risk balance of Forxiga, XigDuo, Invokana, Vokanamet, Jardiance and Synjardy remains favourable subject to the agreed amendments to the product information.
Estonian: Ülaltoodut arvestades leidis ravimiohutuse riskihindamiskomitee, et ravimite Forxiga, XigDuo, Invokana, Vokanamet, Jardiance ja Synjardy kasulikkuse ja riski tasakaal on endiselt soodne, kui ravimiteabesse tehakse kavandatud muudatused.
English: Patients should be advised to contact a doctor in order to be tested for ketoacidosis and to discontinue SGLT2 inhibitor treatment if DKA is suspected or diagnosed.
Estonian: Patsientidele tuleb soovitada, et nad võtaksid ühendust arstiga ketoatsidoosi uurimiseks ja katkestaksid ravi SGLT2 inhibiitoriga, kui kahtlustatakse diabeetilist ketoatsidoosi või see diagnoositakse.
English: Ketone bodies have a low pKa and therefore their accumulation in the blood lead to acidosis.
Estonian: Ketokehadel on väike pKa, mistõttu nende akumuleerumine organismis põhjustab atsidoosi.
English: A safety warning on DKA was issued by the FDA for this therapeutic class in the same month.
Estonian: Samal kuul andis USA Toidu- ja Ravimiamet (FDA) välja selle terapeutilise klassi jaoks diabeetilist ketoatsidoosi puudutava ohutushoiatuse.
English: In order to minimise this risk, the PRAC considered that physicians and patients should be warned through the PI to consider the risk of atypical DKA in the occurrence of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness.
Estonian: Ravimiohutuse riskihindamiskomitee leidis, et riski vähendamiseks tuleb ravimiteabe kaudu arste ja patsiente hoiatada, et nad kaaluksid ebatüüpilise diabeetilise ketoatsidoosi riski mittespetsiifiliste sümptomite, nagu iivelduse, oksendamise, anoreksia, kõhuvalu, ülemäärase janu, hingamisraskuste, segasuse, ebatavalise kurnatuse või unisuse esinemisel.
English: The MAHs are required to submit the final study report to the EMA as they become available.
Estonian: Müügiloa hoidjad peavad esitama lõplikud uuringuaruanded nende valmimisel Euroopa Ravimiametile.
English: This is not an approved indication for SGLT2 inhibitors containing products.
Estonian: See ei ole SGLT2 inhibiitoreid sisaldavate ravimite heakskiidetud näidustus.
English: Atypical presentation of DKA in patients with type 2 diabetes could delay diagnosis and treatment.
Estonian: Diabeetilise ketoatsidoosi ebatüüpiline väljendumine 2. tüüpi diabeediga patsientidel võib aeglustada diagnoosimist ja ravi.
English: • The PRAC therefore, was of the view that the risk of DKA should be minimised by its inclusion in the product information with a warning highlighting to healthcare professional and patients the possible atypical presentation of DKA to be considered in the occurrence of non-specific symptoms, together with the risk factors, and recommendations regarding treatment discontinuation.
Estonian: • Ravimiohutuse riskihindamiskomitee oli seetõttu arvamusel, et diabeetilise ketoatsidoosi riski tuleb vähendada, lisades selle ravimiteabesse hoiatusega, mis rõhutab tervishoiutöötajatele ja patsientidele, et diabeetilise ketoatsidoosi võimalikku ebatüüpilist ilmnemist tuleb kaaluda mittespetsiifiliste sümptomite esinemisel koos riskiteguritega, ja soovitustega seoses ravi katkestamisega.
English: Those studies are expected to enable better characterisation of the risk of DKA and its mechanism and should be included in the RMP of those products.
Estonian: Eeldatakse, et need uuringud aitavad paremini iseloomustada diabeetilise ketoatsidoosi riski ja mehhanismi ning need tuleb lisada vastavate ravimite riskijuhtimiskavadesse.
English: In addition, the low levels of insulin along with a rise in plasma glucagon levels lead to the release of glucose by the liver.
Estonian: Peale selle põhjustab väike insuliinisisaldus koos plasma glükagoonisisalduse suurenemisega glükoosi vabanemist maksast.
English: In conclusion, the PRAC considered that the benefit-risk balance of SGLT2 inhibitors-containing products remained favourable, provided the proposed changes to the product information and the risk management plan are implemented.
Estonian: Kokkuvõttes leidis ravimiohutuse riskihindamiskomitee, et SGLT2 inhibiitoreid sisaldavate ravimite kasulikkuse ja riski tasakaal on endiselt soodne, kui ravimiteabesse ning riskijuhtimiskavasse tehakse kavandatud muudatused.
English: The glucose is partially excreted via the urine, leading to polyuria, dehydration, and compensatory thirst and polydipsia.
Estonian: Glükoos eritub osaliselt uriiniga, viies polüuuria, dehüdratsiooni ning kompensatoorse janu ja polüdipsia tekkimisele.
English: Grounds for PRAC recommendation
Estonian: Ravimiohutuse riskihindamiskomitee soovituse alused
English: The PRAC considered that this information should be included in the PI and, considering that the safety and efficacy of SGLT2 inhibitors have not been established in patients with T1DM, healthcare professionals should be reminded that these should not be used in this indication.
Estonian: Ravimiohutuse riskihindamiskomitee leidis, et see teave tuleb lisada ravimiteabesse, ning arvestades, et SGLT2 inhibiitorite ohutus ja efektiivsus T1DM-iga patsientidel ei ole kindlaks tehtud, tuleb tervishoiutöötajatele meenutada, et neid ravimeid ei tohi sel näidustusel kasutada.
English: Overall summary of the scientific evaluation by the PRAC
Estonian: Ravimiohutuse riskihindamiskomitee teadusliku hindamise üldkokkuvõte
English: However, cases reported with SLGT2 inhibitors occurred in patients with T2DM as well as T1DM.
Estonian: SLGT2 inhibiitoritega teatatud juhud esinesid siiski nii T2DM-i kui ka T1DM-iga patsientidel.
English: Forty-six cases of DKA were also reported in patients on SGLT2 inhibitors for T1DM, which is not currently an approved indication for these products.
Estonian: Samuti teatati 46st diabeetilise ketoatsidoosi juhust patsientidel, kes said SGLT2 inhibiitoreid T1DM-i tõttu, mis ei ole praegu nende ravimite heakskiidetud näidustus.
English: Planned and ongoing Drug Utilisation Studies (DUS) for dapagliflozin- and empagliflozincontaining products are expected to generate more information on the extent and nature of the offlabel use.
Estonian: Oodatakse, et dapagliflosiini ja empagliflosiini sisaldavate ravimite ravimitarbimisuuringud pakuvad registreerimata näidustustel kasutamise ulatuse ja iseloomu kohta rohkem teavet.
English: Non-clinical mechanistic studies are already planned or on-going for dapagliflozin- and empagliflozin-containing products; such study is also required to be undertaken by the MAH of canagliflozin-containing products.
Estonian: Juba on kavandatud või käimas dapagliflosiini ja empagliflosiini sisaldavate ravimite mittekliinilised mehhanistlikud uuringud; sellise uuringu peab läbi viima ka kanagliflosiini sisaldavate ravimite müügiloa hoidja.
English: Several postauthorisation safety studies are planned or ongoing in order to compare the incidence of DKA in SGLT2 inhibitors and other anti-hyperglycaemic agents.
Estonian: Kavandatud või käimas on mitmed müügiloajärgsed ohutusuuringud, et võrrelda diabeetilise ketoatsidoosi esinemissagedust SGLT2 inhibiitorite ja teiste antihüperglükeemiliste ravimite puhul.
English: One hundred and two serious and sometimes life-threatening cases of DKA suggestive of a causal association were identified in T2DM patients for the three active substances, raising thus a safety signal.
Estonian: T2DM-iga patsientidel tuvastati kolme toimeaine puhul 102 põhjuslikule seosele viitavat rasket ja mõnikord eluohtlikku diabeetilise ketoatsidoosi juhtu, andes sellega ohutussignaali.
English: In addition, the PRAC considered that “DKA with atypical presentation” should be added as an important identified risk to the Risk Management Plan (RMP) of those products.
Estonian: Veel leidis ravimiohutuse riskihindamiskomitee, et „ebatüüpiliselt väljendunud diabeetiline ketoatsidoos” tuleb olulise tuvastatud riskina lisada nende ravimite riskijuhtimiskavadesse.
English: This is not an approved indication for SGLT2 inhibitors containing products, nevertheless the PRAC considered that healthcare professionals should be warned of this risk and reminded that patients with T1DM should not be treated with SGLT2 inhibitors.
Estonian: Kuigi see ei ole SGLT2 inhibiitoreid sisaldavate ravimite heakskiidetud näidustus, leidis ravimiohutuse riskihindamiskomitee, et tervishoiutöötajaid tuleb sellest riskist teavitada ja meenutada, et T1DM-iga patsiente ei tohi SGLT2 inhibiitoritega ravida.
English: In a study that reported population-based rates of DKA, the incidence rate of DKA in T2DM patients, requiring hospital admission, was reported to be 0.5 per 1,000 patient-years.
Estonian: Uuringus, milles teatati populatsioonipõhisest diabeetilise ketoatsidoosi sagedusest, oli hospitaliseerimist vajanud diabeetilise ketoatsidoosi esinemissagedus T2DM-iga patsientidel 0,5 juhtu 1000 patsiendiaasta kohta.
English: The atypical presentation of DKA cases in SGLT2 treated diabetes patients, combined with the otherwise non-specific symptoms presented by patients with DKA may delay the diagnosis and therefore lead to the development of more serious or life-threatening conditions.
Estonian: Diabeetilise ketoatsidoosi juhtude ebatüüpiline väljendumine SGLT2 inhibiitoritega ravitud diabeedipatsientidel koos diabeetilise ketoatsidoosiga patsientide mittespetsiifiliste sümptomitega võivad aeglustada diagnoosimist ja viia sellega raskemate või eluohtlike seisundite tekkimisele.
English: Limited data from clinical trials suggest that DKA occurs with common frequency in T1DM patients.
Estonian: Kliiniliste uuringute piiratud andmed viitavad, et diabeetiline ketoatsidoos esineb T1DM-iga patsientidel tavapärase sagedusega.